Critical Comparison: Theratechnologies (OTCMKTS:THERF) vs. Chemomab Therapeutics (NASDAQ:CMMB)

Theratechnologies (OTCMKTS:THERFGet Rating) and Chemomab Therapeutics (NASDAQ:CMMBGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Institutional and Insider Ownership

1.4% of Theratechnologies shares are held by institutional investors. Comparatively, 34.8% of Chemomab Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Theratechnologies and Chemomab Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Theratechnologies $45.18 million 1.62 -$4.66 million ($0.10) -9.50
Chemomab Therapeutics N/A N/A -$27.65 million ($2.76) -0.59

Theratechnologies has higher revenue and earnings than Chemomab Therapeutics. Theratechnologies is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Theratechnologies and Chemomab Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Theratechnologies -11.57% -14.31% -4.25%
Chemomab Therapeutics N/A -77.93% -67.79%

Risk & Volatility

Theratechnologies has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Theratechnologies and Chemomab Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theratechnologies 0 0 0 0 N/A
Chemomab Therapeutics 0 0 0 0 N/A

Chemomab Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 326.83%. Given Chemomab Therapeutics’ higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than Theratechnologies.


Theratechnologies beats Chemomab Therapeutics on 6 of the 11 factors compared between the two stocks.

About Theratechnologies

(Get Rating)

Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.

About Chemomab Therapeutics

(Get Rating)

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.